0001104659-21-124841.txt : 20211008 0001104659-21-124841.hdr.sgml : 20211008 20211008215833 ACCESSION NUMBER: 0001104659-21-124841 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211006 FILED AS OF DATE: 20211008 DATE AS OF CHANGE: 20211008 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Coman David CENTRAL INDEX KEY: 0001886837 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39727 FILM NUMBER: 211316528 MAIL ADDRESS: STREET 1: C/O LIFESCI ACQUISITION II CORP. STREET 2: 250 W 55TH STREET, #3401 CITY: NEW YORK STATE: NY ZIP: 10019 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Science 37 Holdings, Inc. CENTRAL INDEX KEY: 0001819113 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 844278203 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 600 CORPORATE POINTE STREET 2: SUITE 320 CITY: CULVER CITY STATE: CA ZIP: 90230 BUSINESS PHONE: (984)377-3737 MAIL ADDRESS: STREET 1: 600 CORPORATE POINTE STREET 2: SUITE 320 CITY: CULVER CITY STATE: CA ZIP: 90230 FORMER COMPANY: FORMER CONFORMED NAME: Lifesci Acquisition II Corp. DATE OF NAME CHANGE: 20200723 4 1 tm2129593d15_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-10-06 0 0001819113 Science 37 Holdings, Inc. SNCE 0001886837 Coman David 3411 SILVERSIDE RD, TATNALL BLDG #104 WILMINGTON DE 19810 1 1 0 0 CEO and Director Common Stock 2021-10-06 4 A 0 723320 A 723320 D Stock Option 0.28 2021-10-06 4 A 0 3848459 A 2030-04-30 Common Stock 3848459 3848459 D Pursuant to the business combination of LifeSci Acquisition II Corp and Science 37, Inc. ("Old Science 37"), as contemplated by that certain agreement and plan of merger, dated May 6, 2021 (the "Merger Agreement"), (a) each share of common stock of Old Science 37 outstanding immediately prior to the effective time of the business combination was converted into approximately 1.8153 shares of the Issuer's Common Stock (the "Conversion Ratio"); and (b) each outstanding stock option of Old Science 37 was converted into a corresponding option to purchase shares of the Issuer's Common Stock as adjusted for the Conversion Ratio. Stock Option is currently vested and exercisable as to 1,370,560 of the underlying shares, and the remainder will vest in equal monthly installments until fully vested on November 18, 2023, subject to the executive's continued service through the vesting date. /s/ Christine Pellizzari, Attorney-in-Fact for David Coman 2021-10-08